Takeda is to pay $190 million up front and up to $120 million in additional milestones to acquire the private US drug discovery company Intellikine, adding further weight to its growing presence in the oncology sector.
The cash deal, to be routed through Takeda America Holdings, is expected to be completed in January and will give...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?